Previous 10 | Next 10 |
home / stock / mrna / mrna articles
Moderna, Inc. (NASDAQ: MRNA) shares are trading higher after the EMA Committee for Medicinal Products for Human Use adopted an opinion recommending...
On Wednesday, Moderna Inc (NASDAQ: MRNA) conducted an R&D Day event outlining its strategic initiatives across four key areas - Respi...
Wall Street edged higher during Wednesday’s midday session, despite the August CPI report showing the annual inflation rate rising to 3.7%, a...
U.S. stocks traded mixed, with the Dow Jones gaining around 10 points on Wednesday. Here are some big stocks recording gains in today’s sessi...
Moderna Inc (NASDAQ: MRNA) announced its intentions to launch up to 15 new products and advance up to 50 mRNA medicines into clinical trials o...
The Centers for Disease Control and Prevention (CDC) has officially endorsed COVID-19 booster shots for individuals six months and older ...
Benzinga DraftKings Apologizes For 9/11 'Never Forget' Parlay Promotion On Sportsbook App DraftKings Inc (NASDAQ: DKNG) has apologize...
The U.S. Food and Drug Administration on Monday approved and authorized updated COVID-19 vaccines by Moderna Inc (NASDAQ: MRNA) and partners P...
Advancements in healthcare and medicine have helped contribute to the reduction in child mortality rates, plummeting from 185 per 1,000 births a ce...
News, Short Squeeze, Breakout and More Instantly...
CAMBRIDGE, MA / ACCESSWIRE / July 10, 2024 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, August 1, 2024 to report its second quarter 2024 financial results, and provide a corporate update. A live webcast of the c...
CAMBRIDGE, MA AND OSAKA, JAPAN / ACCESSWIRE / July 8, 2024 / Moderna, Inc. (Nasdaq:MRNA) and Mitsubishi Tanabe Pharma Corporation today announced that the companies have entered into a joint agreement regarding the co-promotion of Moderna's mRNA respiratory vaccine portfolio in Japan, including ...
CAMBRIDGE, MA / ACCESSWIRE / July 2, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced a project award of $176 million through the Rapid Response Partnership Vehicle (RRPV) to accelerate the development of mRNA-based pandemic influenza vaccines. The RRPV is a Consortium funded by the Biomedical...